Xenon Pharmaceuticals Inc. — Director's Dealing 2017

Aug 11, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Xenon Pharmaceuticals Inc. (XENE)
CIK: 0001582313
Period of Report: 2017-08-08

Reporting Person: PATOU GARY (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2017-08-08	Common Stock	P	5000	$3.0005	Acquired	5000	Indirect

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	12028	Direct

Footnotes

F1: By Gary & Karen Barbara Patou TTEE Patou Family Trust FBO Gary Patou Karen Barbara Patou